ArticleCell death & disease2025
The SOX12-YBX1-LDHA signaling axis drives metastasis in papillary thyroid carcinoma.
Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- An integrated multiomics-based risk model for predicting the prognosis and immune microenvironment status in patients with papillary thyroid carcinoma.Gland surgery · 2026Article
- The oncogenic potential of SOX12: a comprehensive and perspective view.Journal of translational medicine · 2026Review
- YBX1 as an adaptive RNA hub in cancer: linking state-dependent RNA regulation to tumor immunity, metabolic reprogramming, and therapy resistance.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The sex-determining region Y (SRY)-box (SOX) family plays crucial roles in carcinogenesis and cancer progression. However, the precise function of SOX12 in papillary thyroid carcinoma (PTC) metastasis remains to be investigated. In this study, we analyzed single-cell and bulk RNA sequencing (RNA-seq) datasets and demonstrated significant upregulation of SOX12 in PTC, which is associated with poor prognosis in PTC patients. Functional assays demonstrated that SOX12 overexpression promoted the metastasis of PTC cells, whereas the downregulation of SOX12 markedly reduced the aggressiveness of PTC. By integrating RNA-seq, CUT&Tag, and immunoprecipitation mass spectrometry (IP-MS), we found that SOX12 directly upregulated YBX1 expression and recruited it to the LDHA promoter, thus leading to activation of the TGF-β signaling pathway. Crucially, LDHA knockdown rescued SOX12/YBX1-mediated TGF-β signaling activation and inhibited the migration and invasion of PTC cells. Furthermore, we demonstrated that SOX12 expression is positively correlated with YBX1 and LDHA expression levels in clinical PTC samples. Taken together, these results reveal a critical link between the SOX12-YBX1-LDHA signaling axis and PTC metastasis and suggest that targeting of this signaling node may be a promising alternative therapeutic strategy to combat PTC metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.